Joint technical-scientific recommendation: nonavalent human papillomavirus vaccination for the prevention of oropharyngeal cancer
DOI:
https://doi.org/10.5327/2237-4574-236Abstract
***
References
Instituto Nacional de Câncer José Alencar Gomes da Silva. Estimativa
–2028: Incidência de Câncer no Brasil. Rio de Janeiro: INCA; 2025.
Joura EA, Giuliano AR, Iversen OE, Bouchard C, Mao C, Mehlsen J,
et al. A 9-valent HPV vaccine against infection and intraepithelial
neoplasia in women. N Engl J Med. 2015;372(8):711-23. https://doi.
org/10.1056/nejmoa1405044
Herrero R, Quint W, Hildesheim A, Gonzalez P, Struijk L, Katki HA,
et al. Reduced prevalence of oral human papillomavirus (HPV) 4
years after bivalent HPV vaccination in a randomized clinical trial in
Costa Rica. PLoS One. 2013;8(7):e68329. https://doi.org/10.1371/
journal.pone.0068329
Chaturvedi AK, Engels EA, Pfeiffer RM, Hernandez BY, Xiao W, Kim E,
et al. Human papillomavirus and rising oropharyngeal cancer incidence
in the United States. J Clin Oncol. 2011;29(32):4294-301. https://
doi.org/10.1200/jco.2011.36.4596